Weekly Sepsis Research Analysis
This week’s sepsis literature highlights a convergence of mechanistic host-directed discoveries and microbiome–metabolite biology with practical prognostic and diagnostic advances. A secreted phospholipase (PLA2G5) emerged as a circulating hemolytic mediator and prognostic biomarker with antibody/knockout protection in models. Parallel work identifies microbiome-derived sulfated bile acids and small metabolites that modulate sepsis susceptibility, while mechanistic metabolite/acetylation and pep
Summary
This week’s sepsis literature highlights a convergence of mechanistic host-directed discoveries and microbiome–metabolite biology with practical prognostic and diagnostic advances. A secreted phospholipase (PLA2G5) emerged as a circulating hemolytic mediator and prognostic biomarker with antibody/knockout protection in models. Parallel work identifies microbiome-derived sulfated bile acids and small metabolites that modulate sepsis susceptibility, while mechanistic metabolite/acetylation and peptide-adjuvant studies suggest new therapeutic strategies. Finally, pragmatic prognostic/triage tools (trajectory metrics, triage models) and NET-related biomarker syntheses point to near-term clinical implementation and trial-ready targets.
Selected Articles
1. Secreted phospholipase PLA2G5 acts as a hemolytic factor in sepsis.
PLA2G5 is induced in intestinal cells during sepsis, circulates, and triggers intravascular hemolysis by lipolytic action on erythrocyte membranes. Pla2g5 knockout or neutralizing antibody protects mice from lethal sepsis and improves iron homeostasis; plasma PLA2G5 is elevated in human sepsis and predicts severity and mortality.
Impact: Reveals a previously unrecognized circulating mediator of hemolysis with prognostic value and validates PLA2G5 as a druggable target using genetic and antibody neutralization—high translational potential.
Clinical Implications: Plasma PLA2G5 could be developed as a risk stratification biomarker; PLA2G5 blockade or adjunctive strategies to mitigate hemolysis (heme/hemoglobin scavengers) merit preclinical-to-clinical development.
Key Findings
- PLA2G5 is induced in colon cell types during sepsis and becomes a circulating factor.
- Pla2g5 knockout and a PLA2G5-neutralizing antibody protect mice from lethal sepsis and improve iron homeostasis.
- Circulating PLA2G5 causes intravascular hemolysis via lipolysis of erythrocyte membranes; plasma PLA2G5 is elevated in human sepsis and predicts severity/mortality.
2. d-amino acids restrain macrophage IL-1β release through gasdermin D acetylation.
d-Amino acids increase intracellular acetyl-CoA via PDH activation, induce GSDMD K146 acetylation, block GSDMD oligomerization/pore formation, suppress IL-1β release, and improve survival in LPS sepsis models. Myeloid DDO deletion or d-Ala/d-Glu supplementation recapitulate protective effects.
Impact: Identifies an acetylation-dependent checkpoint on GSDMD-mediated pyroptosis linking immunometabolism to inflammasome effector control and offering a druggable immunometabolic node.
Clinical Implications: Supports development of metabolic or small-molecule strategies (d-amino acid supplementation, DDO/DAAO modulation) to limit IL-1β–driven pathology in sepsis; human PK/safety and broader sepsis-model validation are required.
Key Findings
- Inflammatory macrophages downregulate DAAO/DDO; inhibiting these raises intracellular d-amino acids and suppresses IL-1β.
- d-Amino acids induce GSDMD K146 acetylation, preventing pore-forming oligomerization.
- d-Ala/d-Glu supplementation or myeloid DDO deletion attenuates LPS-induced sepsis in mice.
3. A Muribaculaceae-enriched microbiota exacerbates TLR4-dependent Acinetobacter baumannii-induced hyperinflammatory sepsis.
A Muribaculaceae-dominant gut microbiota (Sangeribacter muris KT1-3) primes macrophages via heat-stable <3 kDa metabolites, lowering the TLR4 activation threshold and producing lethal hyperinflammation in A. baumannii sepsis. The phenotype transfers by FMT/co-housing and is TLR4-dependent (Tlr4−/− mice survive).
Impact: Provides causal, species-level microbiome drivers and small-molecule mediators of a hyperinflammatory sepsis endotype, reframing susceptibility as a microbiota–TLR4 axis and enabling preventive or modulating strategies.
Clinical Implications: Microbiome profiling may identify hyperinflammatory-risk phenotypes; targeting microbiota composition or the responsible metabolites (and TLR4 modulation) are promising translational directions requiring human validation.
Key Findings
- Muribaculaceae-enriched microbiota dominated by Sangeribacter muris KT1-3 predisposes mice to fatal A. baumannii sepsis.
- Lethal hyperinflammatory phenotype transfers via fecal microbiota transplantation and co-housing.
- Heat-stable <3 kDa metabolites prime macrophages and lower TLR4 activation threshold; Tlr4−/− mice are protected.